Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report

A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Zhao, Yan Zhou, Chuan Wang, Yifei Li, Qi Zhu, Yimin Hua, Lina Qiao, Jinlin Wu, Kaiyu Zhou
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	fetal heart atrioventricular block autoantibody prophylactic therapy intravenous immunoglobulin Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/5e24e60e39364527bc567f6b59e92d63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e24e60e39364527bc567f6b59e92d63
record_format	dspace
spelling	oai:doaj.org-article:5e24e60e39364527bc567f6b59e92d632021-11-12T05:11:06ZSuccessful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report2297-055X10.3389/fcvm.2021.759260https://doaj.org/article/5e24e60e39364527bc567f6b59e92d632021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.759260/fullhttps://doaj.org/toc/2297-055XA fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular block occurs, it only takes a short time to progress from first-degree atrioventricular block to complete atrioventricular block, meaning that the damage is often irreversible. Autoimmune—associated AVB, a rare but life—threatening disorder, occurs in 2–5% of pregnancies with positive anti—Ro/SSA (the most common one) and La/SSB antibodies. The perinatal mortality of neonates with AVB outlined in research is approximately 30%. Thus far, for autoimmune-associated AVB fetuses, currently used treatments include corticosteroids, hydroxychloroquine, intravenous immunoglobulin (IVIG), b—sympathomimetic agent, and even plasma exchange. Currently, approaches for preventing the progression and recurrence of a fetal atrioventricular block are still controversial. Here, we reported a baby of successful prevention from the fate of the fetal atrioventricular block by adopting prophylactic comprehensive prenatal therapy.Li ZhaoYan ZhouChuan WangYifei LiQi ZhuYimin HuaLina QiaoJinlin WuKaiyu ZhouFrontiers Media S.A.articlefetal heartatrioventricular blockautoantibodyprophylactic therapyintravenous immunoglobulinDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	fetal heart atrioventricular block autoantibody prophylactic therapy intravenous immunoglobulin Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	fetal heart atrioventricular block autoantibody prophylactic therapy intravenous immunoglobulin Diseases of the circulatory (Cardiovascular) system RC666-701 Li Zhao Yan Zhou Chuan Wang Yifei Li Qi Zhu Yimin Hua Lina Qiao Jinlin Wu Kaiyu Zhou Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
description	A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular block occurs, it only takes a short time to progress from first-degree atrioventricular block to complete atrioventricular block, meaning that the damage is often irreversible. Autoimmune—associated AVB, a rare but life—threatening disorder, occurs in 2–5% of pregnancies with positive anti—Ro/SSA (the most common one) and La/SSB antibodies. The perinatal mortality of neonates with AVB outlined in research is approximately 30%. Thus far, for autoimmune-associated AVB fetuses, currently used treatments include corticosteroids, hydroxychloroquine, intravenous immunoglobulin (IVIG), b—sympathomimetic agent, and even plasma exchange. Currently, approaches for preventing the progression and recurrence of a fetal atrioventricular block are still controversial. Here, we reported a baby of successful prevention from the fate of the fetal atrioventricular block by adopting prophylactic comprehensive prenatal therapy.
format	article
author	Li Zhao Yan Zhou Chuan Wang Yifei Li Qi Zhu Yimin Hua Lina Qiao Jinlin Wu Kaiyu Zhou
author_facet	Li Zhao Yan Zhou Chuan Wang Yifei Li Qi Zhu Yimin Hua Lina Qiao Jinlin Wu Kaiyu Zhou
author_sort	Li Zhao
title	Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_short	Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_full	Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_fullStr	Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_full_unstemmed	Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_sort	successful prevention of fetal autoimmune-mediated heart block by combined therapies with hydroxychloroquine and intravenous immunoglobulin: a case report
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/5e24e60e39364527bc567f6b59e92d63
work_keys_str_mv	AT lizhao successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT yanzhou successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT chuanwang successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT yifeili successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT qizhu successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT yiminhua successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT linaqiao successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT jinlinwu successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT kaiyuzhou successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
_version_	1718431171677782016

Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report

Ejemplares similares